CL2017000582A1 - Nuevos compuestos derivados de piridopirimidinas - Google Patents

Nuevos compuestos derivados de piridopirimidinas

Info

Publication number
CL2017000582A1
CL2017000582A1 CL2017000582A CL2017000582A CL2017000582A1 CL 2017000582 A1 CL2017000582 A1 CL 2017000582A1 CL 2017000582 A CL2017000582 A CL 2017000582A CL 2017000582 A CL2017000582 A CL 2017000582A CL 2017000582 A1 CL2017000582 A1 CL 2017000582A1
Authority
CL
Chile
Prior art keywords
compounds derived
new compounds
pyridopyrimidines
inhibitor
synthesis
Prior art date
Application number
CL2017000582A
Other languages
English (en)
Inventor
Nucci Gilberto De
Original Assignee
Biolab Sanus Farmacêutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmacêutica Ltda filed Critical Biolab Sanus Farmacêutica Ltda
Publication of CL2017000582A1 publication Critical patent/CL2017000582A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN DESCRIBE NUEVOS COMPUESTOS DERIVADOS DE PIRIDOPIRIMIDINA CON ESTRUCTURA REPRESENTADA POR LA FÓRMULA GENERAL (I) O SALES FARMACÉUTICAMENTE ACEPTABLES, O SUS MEZCLAS (EN CUALQUIER PROPORCIÓN), UNA COMPOSICIÓN FARMACÉUTICA QUE LOS CONTIENE, UN MÉTODO DE USO DE LOS NUEVOS COMPUESTOS DERIVADOS DE PIRIDOPIRIMIDINA COMO INHIBIDOR DE LA SÍNTESIS DE NUCLEÓTIDOS CÍCLICOS O COMO INHIBIDOR DE LA SÍNTESIS DE cAMP y cGMP, Y SUS USOS EN EL TRATAMIENTO PROFILÁCTICO O CURATIVO DE LA DIARREA, COLITIS Y SÍNDROME DEL INTESTINO IRRITABLE.</p>
CL2017000582A 2014-09-12 2017-03-09 Nuevos compuestos derivados de piridopirimidinas CL2017000582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049506P 2014-09-12 2014-09-12

Publications (1)

Publication Number Publication Date
CL2017000582A1 true CL2017000582A1 (es) 2017-11-24

Family

ID=55454107

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000582A CL2017000582A1 (es) 2014-09-12 2017-03-09 Nuevos compuestos derivados de piridopirimidinas

Country Status (18)

Country Link
US (2) US10280162B2 (es)
EP (1) EP3191099B1 (es)
JP (1) JP6661606B2 (es)
KR (1) KR20170054408A (es)
CN (2) CN114751905A (es)
AR (1) AR101813A1 (es)
AU (1) AU2015316120B2 (es)
BR (1) BR112017004919A2 (es)
CA (1) CA2958331C (es)
CL (1) CL2017000582A1 (es)
CO (1) CO2017001709A2 (es)
ES (1) ES2701273T3 (es)
HU (1) HUE040387T2 (es)
IL (1) IL250968B (es)
MX (1) MX2017003067A (es)
PL (1) PL3191099T3 (es)
PT (1) PT3191099T (es)
WO (1) WO2016037255A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523211A (ja) 2014-08-04 2017-08-17 ドレクセル ユニバーシティ 新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300543T1 (de) * 2000-06-26 2005-08-15 Lilly Icos Llc Kondensierte pyrazindionderivate als pde5 inhibitore
BR0113628A (pt) 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
US6960587B2 (en) * 2000-11-08 2005-11-01 Lilly Icos Llc Condensed pyrazindione derivatives as PDE inhibitors
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
CA2651573C (en) * 2006-05-23 2011-12-06 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
WO2008008704A2 (en) * 2006-07-11 2008-01-17 University Of Texas Health Science Center Inhibitors of cyclic nucleotide synthesis and their use for therapy of various diseases
US7474231B2 (en) * 2006-07-12 2009-01-06 Alcatel-Lucent Usa Inc. Radio communications for vehicle speed adjustment
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
WO2013183016A1 (en) * 2012-06-06 2013-12-12 L'oreal Active compounds for combating greasy skin

Also Published As

Publication number Publication date
CA2958331A1 (en) 2016-03-17
US10280162B2 (en) 2019-05-07
US20180111926A2 (en) 2018-04-26
WO2016037255A3 (en) 2016-06-30
CN114751905A (zh) 2022-07-15
WO2016037255A2 (en) 2016-03-17
PL3191099T3 (pl) 2019-07-31
US10822333B2 (en) 2020-11-03
IL250968B (en) 2020-03-31
JP6661606B2 (ja) 2020-03-11
CO2017001709A2 (es) 2017-03-31
KR20170054408A (ko) 2017-05-17
AR101813A1 (es) 2017-01-11
EP3191099A2 (en) 2017-07-19
ES2701273T3 (es) 2019-02-21
US20160075702A1 (en) 2016-03-17
JP2017526666A (ja) 2017-09-14
CN107074847A (zh) 2017-08-18
AU2015316120A1 (en) 2017-01-12
HUE040387T2 (hu) 2019-03-28
MX2017003067A (es) 2017-06-14
EP3191099B1 (en) 2018-11-14
PT3191099T (pt) 2018-12-18
US20190218216A1 (en) 2019-07-18
CA2958331C (en) 2019-12-17
BR112017004919A2 (pt) 2017-12-12
IL250968A0 (en) 2017-04-30
AU2015316120B2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
CR20180069A (es) Derivados de la sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CR20160400A (es) Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
ECSP17039611A (es) Derivados de quinazolina utilizados para tratar el vih
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2016010071A (es) Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
MX2017001553A (es) Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.